Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4Dermatologic 2Sarcoma 1

Conditions

Sezary Syndrome 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, Biphenotypic, Acute 1Leukemia 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 48fludarabine phosphate 28Filgrastim 27Radiotherapy 26Antilymphocyte Serum 26Busulfan 24Cyclosporine 23Peripheral Blood Stem Cell Transplantation 19Mycophenolic Acid 18Cord Blood Stem Cell Transplantation 17Methylprednisolone 16Methotrexate 16Melphalan 15Etoposide 15Tacrolimus 12Whole-Body Irradiation 11Cytarabine 9Thiotepa 6Vincristine 5Psychiatric Rehabilitation 5sargramostim 4aldesleukin 4Sirolimus 4Leucovorin 4Granulocyte Colony-Stimulating Factor 4fludarabine 3Prednisone 3Early Intervention, Educational 3Daunorubicin 3glucarpidase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × B3(Fv)-PE38KDEL recombinant immunotoxin × Sarcoma × Clear all
NCT00085150 2015-04-30

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
DermatologicLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Leukemia, Lymphoma, Mycosis Fungoides, Recurrence, Sezary Syndrome, Leukemia, Biphenotypic, Acute, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡